Antidiabetic PPARγ-Activator Rosiglitazone Reduces MMP-9 Serum Levels in Type 2 Diabetic Patients With Coronary Artery Disease
Open Access
- 1 February 2003
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 23 (2), 283-288
- https://doi.org/10.1161/01.atv.0000054195.35121.5e
Abstract
Background— Matrix metalloproteinases (MMPs) are critically involved in the development of unstable plaques. Although arteriosclerotic lesions in patients with diabetes mellitus are more unstable than those of nondiabetic subjects, nothing is known about serum levels of MMPs in these patients or about mechanisms to modulate MMP levels. We investigated MMP levels in diabetic and nondiabetic coronary artery disease (CAD) patients and performed a clinical trial to assess the effect of the PPARγ-activating, antidiabetic thiazolidinedione rosiglitazone on MMP levels in diabetic CAD patients. Methods and Results— In CAD patients, MMP-2, -8, and -9 serum levels were significantly higher in type 2 diabetic subjects compared with age-, sex-, and body mass index–matched nondiabetics. Thirty-nine diabetic patients with CAD were randomized to receive rosiglitazone 4 mg (twice daily) or placebo for 12 weeks. Rosiglitazone treatment, but not placebo, significantly reduced MMP-9 levels already after 2 weeks by −19.6% (−38.3% to 8.6%, P Conclusion— MMP-9 levels are increased in type 2 diabetic patients with CAD, and treatment of these patients with the antidiabetic PPARγ-activator rosiglitazone significantly reduces MMP-9, tumor necrosis factor-α, and SAA serum levels. These data support anti-inflammatory and potential antiatherogenic effects of thiazolidinediones.Keywords
This publication has 19 references indexed in Scilit:
- Evidence for a Matrix Metalloproteinase Induction/Activation System in Arterial Vasculature and Decreased Synthesis and Activity in DiabetesDiabetes, 2002
- Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.Circulation, 2002
- Diabetes and AtherosclerosisJAMA, 2002
- Peroxisome proliferator-activated receptor γ and atherosclerosisCurrent Hypertension Reports, 2002
- Peroxisome proliferator–activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor–deficient miceJCI Insight, 2000
- Thiazolidinediones: an updateThe Lancet, 2000
- Modulation of Vascular Inflammation In Vitro and In Vivo by Peroxisome Proliferator–Activated Receptor-γ ActivatorsCirculation, 2000
- Atherosclerosis — An Inflammatory DiseaseNew England Journal of Medicine, 1999
- Troglitazone Reduces LDL Oxidation and Lowers Plasma E-selectin Concentration in NIDDM PatientsDiabetes, 1998
- Circulating Vascular Cell Adhesion Molecule-1 (VCAM-1) in Atherosclerotic NIDDM PatientsDiabetes, 1997